Skip to main content
  1. Home
  2. Health and social care
  3. Medicines, medical devices
  4. Vigilance, safety alerts and guidance
  5. Alerts and recalls

Drug Safety Update

From:
Medicines and Healthcare products Regulatory Agency

159 updates

159 updates
About Infectious disease
  • The Black Triangle Scheme (▼ or ▼*)

    Continued monitoring of medicines with a black triangle status.

    • Therapeutic area: Anaesthesia and intensive care and 6 others
    • Published:
  • Piperacillin/tazobactam: compatibility of generics is different from brand leader (tazocin)

    Generic piperacillin/tazobactam products have different compatibilities with other medicines compared with tazocin, raising a risk of serious medication errors.

    • Therapeutic area: Infectious disease
    • Published:
  • Norfloxacin: restricted use in urinary infections

    The European Medicines Agency (EMA) has concluded that oral fluoroquinolone norfloxacin (Utinor) shouldn't be used to treat acute or chronic, complicated pyelonephritis.

    • Therapeutic area: Infectious disease and 1 others
    • Published:
  • Monitoring the safety of antiretroviral drugs

    Healthcare professionals should monitor the use and safety of antiretroviral drugs for the treatment of HIV as they are advanced.

    • Therapeutic area: Infectious disease
    • Published:
  • Telbivudine and pegylated interferon: risk of peripheral neuropathy

    Patients who take telbivudine and pegylated interferon are at increased risk of peripheral neuropathy and should stop taking both medicines if symptoms occur.

    • Therapeutic area: GI, hepatology and pancreatic disorders and 2 others
    • Published:
  • Tazocin (piperacillin/tazobactam): new formulation

    Tazocin (piperacillin/tazobactam) has been reformulated to meet European Pharmacopoeia requirements on particle size.

    • Therapeutic area: Infectious disease
    • Published:
  • Ecoflac infusion solutions: risk of air embolism

    To avoid the risk of air embolism, these products should not be infused under pressure.

    • Therapeutic area: Anaesthesia and intensive care and 22 others
    • Published:
  • Corticosteroids: early psychiatric side-effects

    Risk of early psychiatric side-effects is one of several important safety issues for healthcare professionals to discuss with patients and carers, who should seek urgent medical advice in the event of any worrying symptoms.

    • Therapeutic area: Anaesthesia and intensive care and 9 others
    • Published:
  • Linezolid: restricted indication

    Linezolid is not active against infections caused by Gram-negative pathogens, and treatment should be started only after specialist microbiological advice.

    • Therapeutic area: Infectious disease
    • Published: